Cysteine elevation in levodopa‐treated patients with Parkinson's disease
Identifieur interne : 002370 ( Main/Curation ); précédent : 002369; suivant : 002371Cysteine elevation in levodopa‐treated patients with Parkinson's disease
Auteurs : Thomas Müller [Allemagne] ; Wilfried Kuhn [Allemagne]Source :
- Movement Disorders [ 0885-3185 ] ; 2009-04-30.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
- Adult, Aged, Analysis of Variance, Antiparkinson Agents (therapeutic use), Cohort Studies, Cysteine, Cysteine (blood), Female, Glycine (blood), Homocystein, Human, Humans, Levodopa, Levodopa (therapeutic use), Linear Models, Male, Middle Aged, Nervous system diseases, Parkinson Disease (blood), Parkinson Disease (drug therapy), Parkinson disease, Parkinson's disease, Severity of Illness Index, Treatment, cysteine, homocysteine, levodopa.
- MESH :
- chemical , blood : Cysteine, Glycine.
- chemical , therapeutic use : Antiparkinson Agents, Levodopa.
- blood : Parkinson Disease.
- drug therapy : Parkinson Disease.
- Adult, Aged, Analysis of Variance, Cohort Studies, Female, Humans, Linear Models, Male, Middle Aged, Severity of Illness Index.
Abstract
Homocysteine, cysteine, and cysteinyl‐glycine are all metabolically interrelated. Levodopa/decarboxylase inhibitor (LD/DCI) administration increases total homocysteine (tHcy) plasma levels. Objectives were to investigate associations between LD/DCI intake, concentrations of tHcy, cysteine, and cysteinyl‐glycine in PD patients and healthy controls. Cysteine levels were significant lower in controls and PD patients with tHcy below the treshold of 15 [μmol/L] when compared with PD patients with tHcy above 15. Cysteinyl‐glycine did not significantly differ between the three cohorts. Significant associations appeared between tHcys and cysteine in PD patients. tHcy and cysteine concentrations correlated to LD/DCI intake and severity of PD. The cysteine increase may be due to the significant higher dosing of daily LD/DCI and the significant higher morning LD/DCI dose 1 hour before blood sampling in PD patients with tHcy above 15 when compared with the remaining PD patients and the controls. The correlation outcomes support the view that LD/DCI intake may also increase cysteine. © 2009 Movement Disorder Society
Url:
DOI: 10.1002/mds.22482
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000C65
- to stream Istex, to step Curation: Pour aller vers cette notice dans l'étape Curation :000C65
- to stream Istex, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000F72
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001D95
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :001D95
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001E73
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :002582
- to stream Ncbi, to step Curation: Pour aller vers cette notice dans l'étape Curation :002582
- to stream Ncbi, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :002582
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :002C31
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000E87
- to stream PascalFrancis, to step Curation: Pour aller vers cette notice dans l'étape Curation :001E32
- to stream PascalFrancis, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000F26
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :003023
Links to Exploration step
ISTEX:77920EA0F633467AC865D3D13A78773248A29A59Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cysteine elevation in levodopa‐treated patients with Parkinson's disease</title>
<author><name sortKey="Muller, Thomas" sort="Muller, Thomas" uniqKey="Muller T" first="Thomas" last="Müller">Thomas Müller</name>
</author>
<author><name sortKey="Kuhn, Wilfried" sort="Kuhn, Wilfried" uniqKey="Kuhn W" first="Wilfried" last="Kuhn">Wilfried Kuhn</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:77920EA0F633467AC865D3D13A78773248A29A59</idno>
<date when="2009" year="2009">2009</date>
<idno type="doi">10.1002/mds.22482</idno>
<idno type="url">https://api.istex.fr/document/77920EA0F633467AC865D3D13A78773248A29A59/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000C65</idno>
<idno type="wicri:Area/Istex/Curation">000C65</idno>
<idno type="wicri:Area/Istex/Checkpoint">000F72</idno>
<idno type="wicri:doubleKey">0885-3185:2009:Muller T:cysteine:elevation:in</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:19243072</idno>
<idno type="wicri:Area/PubMed/Corpus">001D95</idno>
<idno type="wicri:Area/PubMed/Curation">001D95</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001E73</idno>
<idno type="wicri:Area/Ncbi/Merge">002582</idno>
<idno type="wicri:Area/Ncbi/Curation">002582</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002582</idno>
<idno type="wicri:Area/Main/Merge">002C31</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:09-0223229</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000E87</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001E32</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000F26</idno>
<idno type="wicri:doubleKey">0885-3185:2009:Muller T:cysteine:elevation:in</idno>
<idno type="wicri:Area/Main/Merge">003023</idno>
<idno type="wicri:Area/Main/Curation">002370</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Cysteine elevation in levodopa‐treated patients with Parkinson's disease</title>
<author><name sortKey="Muller, Thomas" sort="Muller, Thomas" uniqKey="Muller T" first="Thomas" last="Müller">Thomas Müller</name>
<affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Neurology, St. Joseph Hospital Berlin‐Weißensee, Berlin</wicri:regionArea>
<placeName><region type="land" nuts="3">Berlin</region>
<settlement type="city">Berlin</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Neurology, St. Josef Hospital, Ruhr University Bochum, Bochum</wicri:regionArea>
<wicri:noRegion>Bochum</wicri:noRegion>
<wicri:noRegion>Bochum</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kuhn, Wilfried" sort="Kuhn, Wilfried" uniqKey="Kuhn W" first="Wilfried" last="Kuhn">Wilfried Kuhn</name>
<affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Neurology, St. Josef Hospital, Ruhr University Bochum, Bochum</wicri:regionArea>
<wicri:noRegion>Bochum</wicri:noRegion>
<wicri:noRegion>Bochum</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Neurology, Leopoldina Hospital, Gustav, Schweinfurt</wicri:regionArea>
<wicri:noRegion>Schweinfurt</wicri:noRegion>
<wicri:noRegion>Schweinfurt</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2009-04-30">2009-04-30</date>
<biblScope unit="vol">24</biblScope>
<biblScope unit="issue">6</biblScope>
<biblScope unit="page" from="929">929</biblScope>
<biblScope unit="page" to="932">932</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">77920EA0F633467AC865D3D13A78773248A29A59</idno>
<idno type="DOI">10.1002/mds.22482</idno>
<idno type="ArticleID">MDS22482</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Analysis of Variance</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Cohort Studies</term>
<term>Cysteine</term>
<term>Cysteine (blood)</term>
<term>Female</term>
<term>Glycine (blood)</term>
<term>Homocystein</term>
<term>Human</term>
<term>Humans</term>
<term>Levodopa</term>
<term>Levodopa (therapeutic use)</term>
<term>Linear Models</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Nervous system diseases</term>
<term>Parkinson Disease (blood)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson disease</term>
<term>Parkinson's disease</term>
<term>Severity of Illness Index</term>
<term>Treatment</term>
<term>cysteine</term>
<term>homocysteine</term>
<term>levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Cysteine</term>
<term>Glycine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Analysis of Variance</term>
<term>Cohort Studies</term>
<term>Female</term>
<term>Humans</term>
<term>Linear Models</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Severity of Illness Index</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Cystéine</term>
<term>Homme</term>
<term>Homocystéine</term>
<term>Lévodopa</term>
<term>Maladie de Parkinson</term>
<term>Pathologie du système nerveux</term>
<term>Traitement</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Homocysteine, cysteine, and cysteinyl‐glycine are all metabolically interrelated. Levodopa/decarboxylase inhibitor (LD/DCI) administration increases total homocysteine (tHcy) plasma levels. Objectives were to investigate associations between LD/DCI intake, concentrations of tHcy, cysteine, and cysteinyl‐glycine in PD patients and healthy controls. Cysteine levels were significant lower in controls and PD patients with tHcy below the treshold of 15 [μmol/L] when compared with PD patients with tHcy above 15. Cysteinyl‐glycine did not significantly differ between the three cohorts. Significant associations appeared between tHcys and cysteine in PD patients. tHcy and cysteine concentrations correlated to LD/DCI intake and severity of PD. The cysteine increase may be due to the significant higher dosing of daily LD/DCI and the significant higher morning LD/DCI dose 1 hour before blood sampling in PD patients with tHcy above 15 when compared with the remaining PD patients and the controls. The correlation outcomes support the view that LD/DCI intake may also increase cysteine. © 2009 Movement Disorder Society</div>
</front>
</TEI>
<double idat="0885-3185:2009:Muller T:cysteine:elevation:in"><INIST><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Cysteine Elevation in Levodopa-Treated Patients with Parkinson's Disease</title>
<author><name sortKey="Muller, Thomas" sort="Muller, Thomas" uniqKey="Muller T" first="Thomas" last="Müller">Thomas Müller</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Department of Neurology, St. Joseph Hospital Berlin-Weissensee</s1>
<s2>Berlin</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<placeName><region type="land" nuts="3">Berlin</region>
<settlement type="city">Berlin</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurology, St. Josef Hospital, Ruhr University Bochum</s1>
<s2>Bochum</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>Bochum</wicri:noRegion>
<wicri:noRegion>Ruhr University Bochum</wicri:noRegion>
<wicri:noRegion>Bochum</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kuhn, Wilfried" sort="Kuhn, Wilfried" uniqKey="Kuhn W" first="Wilfried" last="Kuhn">Wilfried Kuhn</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurology, St. Josef Hospital, Ruhr University Bochum</s1>
<s2>Bochum</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>Bochum</wicri:noRegion>
<wicri:noRegion>Ruhr University Bochum</wicri:noRegion>
<wicri:noRegion>Bochum</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Neurology, Leopoldina Hospital, Gustav</s1>
<s2>Schweinfurt</s2>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>Schweinfurt</wicri:noRegion>
<wicri:noRegion>Gustav</wicri:noRegion>
<wicri:noRegion>Schweinfurt</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">09-0223229</idno>
<date when="2009">2009</date>
<idno type="stanalyst">PASCAL 09-0223229 INIST</idno>
<idno type="RBID">Pascal:09-0223229</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000E87</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001E32</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000F26</idno>
<idno type="wicri:doubleKey">0885-3185:2009:Muller T:cysteine:elevation:in</idno>
<idno type="wicri:Area/Main/Merge">003023</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Cysteine Elevation in Levodopa-Treated Patients with Parkinson's Disease</title>
<author><name sortKey="Muller, Thomas" sort="Muller, Thomas" uniqKey="Muller T" first="Thomas" last="Müller">Thomas Müller</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Department of Neurology, St. Joseph Hospital Berlin-Weissensee</s1>
<s2>Berlin</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<placeName><region type="land" nuts="3">Berlin</region>
<settlement type="city">Berlin</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurology, St. Josef Hospital, Ruhr University Bochum</s1>
<s2>Bochum</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>Bochum</wicri:noRegion>
<wicri:noRegion>Ruhr University Bochum</wicri:noRegion>
<wicri:noRegion>Bochum</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kuhn, Wilfried" sort="Kuhn, Wilfried" uniqKey="Kuhn W" first="Wilfried" last="Kuhn">Wilfried Kuhn</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurology, St. Josef Hospital, Ruhr University Bochum</s1>
<s2>Bochum</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>Bochum</wicri:noRegion>
<wicri:noRegion>Ruhr University Bochum</wicri:noRegion>
<wicri:noRegion>Bochum</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Neurology, Leopoldina Hospital, Gustav</s1>
<s2>Schweinfurt</s2>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>Schweinfurt</wicri:noRegion>
<wicri:noRegion>Gustav</wicri:noRegion>
<wicri:noRegion>Schweinfurt</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2009">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cysteine</term>
<term>Homocystein</term>
<term>Human</term>
<term>Levodopa</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Maladie de Parkinson</term>
<term>Pathologie du système nerveux</term>
<term>Cystéine</term>
<term>Lévodopa</term>
<term>Traitement</term>
<term>Homme</term>
<term>Homocystéine</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Homocysteine, cysteine, and cysteinyl-glycine are an metabolically interrelated. Levodopa/decarboxylase inhibitor (LD/DCI) administration increases total homocysteine (tHcy) plasma levels. Objectives were to investigate associations between LD/DCI intake, concentrations of tHcy, cysteine, and cysteinyl-glycine in PD patients and healthy controls. Cysteine levels were significant lower in controls and PD patients with tHcy below the treshold of 15 [μmol/L] when compared with PD patients with tHcy above 15. Cysteinyl-glycine did not significantly differ between the three cohorts. Significant associations appeared between tHcys and cysteine in PD patients. tHcy and cysteine concentrations correlated to LD/DCI intake and severity of PD. The cysteine increase may be due to the significant higher dosing of daily LD/DCI and the significant higher morning LD/DCI dose 1 hour before blood sampling in PD patients with tHcy above 15 when compared with the remaining PD patients and the controls. The correlation outcomes support the view that LD/ DCI intake may also increase cysteine.</div>
</front>
</TEI>
</INIST>
<ISTEX><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cysteine elevation in levodopa‐treated patients with Parkinson's disease</title>
<author><name sortKey="Muller, Thomas" sort="Muller, Thomas" uniqKey="Muller T" first="Thomas" last="Müller">Thomas Müller</name>
</author>
<author><name sortKey="Kuhn, Wilfried" sort="Kuhn, Wilfried" uniqKey="Kuhn W" first="Wilfried" last="Kuhn">Wilfried Kuhn</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:77920EA0F633467AC865D3D13A78773248A29A59</idno>
<date when="2009" year="2009">2009</date>
<idno type="doi">10.1002/mds.22482</idno>
<idno type="url">https://api.istex.fr/document/77920EA0F633467AC865D3D13A78773248A29A59/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000C65</idno>
<idno type="wicri:Area/Istex/Curation">000C65</idno>
<idno type="wicri:Area/Istex/Checkpoint">000F72</idno>
<idno type="wicri:doubleKey">0885-3185:2009:Muller T:cysteine:elevation:in</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:19243072</idno>
<idno type="wicri:Area/PubMed/Corpus">001D95</idno>
<idno type="wicri:Area/PubMed/Curation">001D95</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001E73</idno>
<idno type="wicri:Area/Ncbi/Merge">002582</idno>
<idno type="wicri:Area/Ncbi/Curation">002582</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002582</idno>
<idno type="wicri:Area/Main/Merge">002C31</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Cysteine elevation in levodopa‐treated patients with Parkinson's disease</title>
<author><name sortKey="Muller, Thomas" sort="Muller, Thomas" uniqKey="Muller T" first="Thomas" last="Müller">Thomas Müller</name>
<affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Neurology, St. Joseph Hospital Berlin‐Weißensee, Berlin</wicri:regionArea>
<placeName><region type="land" nuts="3">Berlin</region>
<settlement type="city">Berlin</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Neurology, St. Josef Hospital, Ruhr University Bochum, Bochum</wicri:regionArea>
<wicri:noRegion>Bochum</wicri:noRegion>
<wicri:noRegion>Bochum</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kuhn, Wilfried" sort="Kuhn, Wilfried" uniqKey="Kuhn W" first="Wilfried" last="Kuhn">Wilfried Kuhn</name>
<affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Neurology, St. Josef Hospital, Ruhr University Bochum, Bochum</wicri:regionArea>
<wicri:noRegion>Bochum</wicri:noRegion>
<wicri:noRegion>Bochum</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Neurology, Leopoldina Hospital, Gustav, Schweinfurt</wicri:regionArea>
<wicri:noRegion>Schweinfurt</wicri:noRegion>
<wicri:noRegion>Schweinfurt</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2009-04-30">2009-04-30</date>
<biblScope unit="vol">24</biblScope>
<biblScope unit="issue">6</biblScope>
<biblScope unit="page" from="929">929</biblScope>
<biblScope unit="page" to="932">932</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">77920EA0F633467AC865D3D13A78773248A29A59</idno>
<idno type="DOI">10.1002/mds.22482</idno>
<idno type="ArticleID">MDS22482</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Analysis of Variance</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Cohort Studies</term>
<term>Cysteine (blood)</term>
<term>Female</term>
<term>Glycine (blood)</term>
<term>Humans</term>
<term>Levodopa (therapeutic use)</term>
<term>Linear Models</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Parkinson Disease (blood)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson's disease</term>
<term>Severity of Illness Index</term>
<term>cysteine</term>
<term>homocysteine</term>
<term>levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Cysteine</term>
<term>Glycine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Analysis of Variance</term>
<term>Cohort Studies</term>
<term>Female</term>
<term>Humans</term>
<term>Linear Models</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Severity of Illness Index</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Homocysteine, cysteine, and cysteinyl‐glycine are all metabolically interrelated. Levodopa/decarboxylase inhibitor (LD/DCI) administration increases total homocysteine (tHcy) plasma levels. Objectives were to investigate associations between LD/DCI intake, concentrations of tHcy, cysteine, and cysteinyl‐glycine in PD patients and healthy controls. Cysteine levels were significant lower in controls and PD patients with tHcy below the treshold of 15 [μmol/L] when compared with PD patients with tHcy above 15. Cysteinyl‐glycine did not significantly differ between the three cohorts. Significant associations appeared between tHcys and cysteine in PD patients. tHcy and cysteine concentrations correlated to LD/DCI intake and severity of PD. The cysteine increase may be due to the significant higher dosing of daily LD/DCI and the significant higher morning LD/DCI dose 1 hour before blood sampling in PD patients with tHcy above 15 when compared with the remaining PD patients and the controls. The correlation outcomes support the view that LD/DCI intake may also increase cysteine. © 2009 Movement Disorder Society</div>
</front>
</TEI>
</ISTEX>
</double>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002370 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 002370 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Curation |type= RBID |clé= ISTEX:77920EA0F633467AC865D3D13A78773248A29A59 |texte= Cysteine elevation in levodopa‐treated patients with Parkinson's disease }}
![]() | This area was generated with Dilib version V0.6.23. | ![]() |